Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Yaqrit Prepares Phase 3 for Ammonia Scavenger in Hepatic Encephalopathy
Details : An ammonia scavenger, L-ornithine phenylacetate (OPA), is being evaluated for treatment of patients suffering from acute hepatic encephalopathy.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function
Details : MNK-6105 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hepatic Encephalopathy.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
October 16, 2019
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
OCR002-SP103 - Oral Immediate Release Study
Details : OCR-002 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fibrosis.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
February 20, 2019
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ornithine Phenylacetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatic Encephalopathy.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
October 21, 2013
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Emergency Use of OCR-002 in Acute Liver Failure (ALF)
Details : OCR-002 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Liver Failure, Acute.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
July 06, 2012
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Medical University of South Carolina | National Institute of Diabetes and Digestive and Kidney Diseases | Ocera Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ornithine Phenylacetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Failure, Acute.
Product Name : Undisclosed
Product Type : Amino Acid
Upfront Cash : Inapplicable
March 08, 2012
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Medical University of South Carolina | National Institute of Diabetes and Digestive and Kidney Diseases | Ocera Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
